BioCardia Reports Successful Consultation with Japans PMDA on BCDA-01 RegistrationSunnyvale, California December 4, 2024 BioCardia, Inc. has recently disclosed a significant achievement regarding its lead therapeutic asset, BCDA-0
| BCDA Stock | USD 2.13 0.11 4.91% |
About 62% of Biocardia's investor base is looking to short. The analysis of the overall investor sentiment regarding Biocardia suggests that many traders are alarmed. The current market sentiment, together with Biocardia's historical and current headlines, can help investors time the market. In addition, many technical investors use Biocardia stock news signals to limit their universe of possible portfolio assets.
Biocardia |
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read BioCardias 8K filing here. About BioCardia BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead
Read at thelincolnianonline.com
 |
Biocardia Fundamental Analysis
We analyze Biocardia's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biocardia using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biocardia based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Biocardia is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Biocardia Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biocardia stock to make a market-neutral strategy. Peer analysis of Biocardia could also be used in its relative valuation, which is a method of valuing Biocardia by comparing valuation metrics with similar companies.
Peers
Biocardia Related Equities
| ABVC | ABVC Biopharma | 3.77 | ||||
| NGENF | NervGen Pharma | 0.95 | ||||
| ADAG | Adagene | 0.51 | ||||
| INDP | Indaptus Therapeutics | 2.06 | ||||
| AVTE | Aerovate Therapeutics | 3.41 | ||||
| ANTX | AN2 Therapeutics | 3.85 | ||||
| RZLT | Rezolute | 5.95 | ||||
| FBRX | Forte Biosciences | 8.54 | ||||
| KTTA | Pasithea Therapeutics | 8.57 | ||||
| ACRV | Acrivon Therapeutics, | 10.33 | ||||
| ANEB | Anebulo Pharmaceuticals | 10.43 | ||||
| MLYS | Mineralys Therapeutics, | 11.87 | ||||
| PTIX | Protagenic Therapeutics | 12.73 | ||||
| ERAS | Erasca | 13.82 |
Complementary Tools for Biocardia Stock analysis
When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |